Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer outcomes and toxicity

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 5, 2013, Pages 461-466

  Mitchell, Melissa P ^a   Abboud, Mirna ^a   Eng, Cathy ^a   Beddar, A Sam ^a   Krishnan, Sunil ^a   Delclos, Marc E ^a   Crane, Christopher H ^a   Das, Prajnan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anal cancer; Intensity modulated radiation therapy; Local control; Toxicity

Indexed keywords

EID: 84914665811     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31827e52a3     Document Type: Article

References (19)

1. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy versus fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. J Am Med Assoc. 2008;299:1911-1921.
2. Chen YJ, Liu A, Tsai PT, et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys. 2005;63:274-281.
3. Menkarios C, Azria D, Laliberté B, et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol. 2007;2:41.
4. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63:354-361.
5. Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys. 2010;78:1413-1419.
6. Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensitymodulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82:153-158.
7. Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117:3342-3351.
8. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25:4581-4586.
9. Defoe SG, Beriwal S, Jones H, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma-clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol. 2012;24:424-431.
10. Kachnic LA, Winter KA, Myerson RJ, et al. RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2009;75(suppl 3):S5, abstract 10.
11. Kachnic LA, Winter KA, Myerson RJ, et al. Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. J Clin Oncol. 2011;29(suppl. 4), abstract 368.
12. Briere TM, Das P, Beddar S, et al. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients. Radiother Oncol. 2012;104:161-166.
13. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed June 1, 2012.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68:794-800.
16. Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007-4013.
17. James R, Wan S, Glynne-Jones RA. Randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). J Clin Oncol. 2009;27(suppl. 18):797s, abstract LBA4009.
18. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824-830.
19. Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009;27:1116-1121.